Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

LLM 2021 | Actionable pathways that could be targeted in myeloma

Rafael Fonseca, MD, Mayo Clinic, Phoenix, AZ, discusses interesting and promising actionable pathways that could be targeted in the treatment of multiple myeloma. The development of compounds targeting genes such as MMSET, associated with the translocation t(4; 14), is currently in its early stages. Agents targeting RAS mutations are also under development. Additionally, targeting the BRAF mutation may be of interest in myeloma as well. This interview took place at the Lymphoma, Leukemia & Myeloma Congress 2021.